US8703781 — Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Method of Use · Assigned to GlaxoSmithKline LLC · Expires 2030-10-15 · 4y remaining
What this patent protects
This patent protects a novel combination of a MEK inhibitor and a B-Raf inhibitor for use in treating certain conditions.
USPTO Abstract
A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophen-}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1713 |
— | dabrafenib-mesylate |
U-2305 |
— | trametinib-dimethyl-sulfoxide |
U-2302 |
— | trametinib-dimethyl-sulfoxide |
U-2037 |
— | trametinib-dimethyl-sulfoxide |
U-3564 |
— | trametinib-dimethyl-sulfoxide |
U-3565 |
— | dabrafenib-mesylate |
U-2296 |
— | dabrafenib-mesylate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.